Novo Nordisk A/S (NYSE:NVO) Shares Sold by Moody National Bank Trust Division

Moody National Bank Trust Division reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVOGet Rating) by 74.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,107 shares of the company’s stock after selling 6,000 shares during the quarter. Moody National Bank Trust Division’s holdings in Novo Nordisk A/S were worth $234,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Park National Corp OH boosted its position in shares of Novo Nordisk A/S by 53.4% during the 2nd quarter. Park National Corp OH now owns 2,849 shares of the company’s stock worth $317,000 after acquiring an additional 992 shares in the last quarter. Chemung Canal Trust Co. boosted its position in shares of Novo Nordisk A/S by 7.7% during the 2nd quarter. Chemung Canal Trust Co. now owns 15,407 shares of the company’s stock worth $1,717,000 after acquiring an additional 1,101 shares in the last quarter. Mathes Company Inc. boosted its position in shares of Novo Nordisk A/S by 793.5% during the 1st quarter. Mathes Company Inc. now owns 1,930 shares of the company’s stock worth $214,000 after acquiring an additional 1,714 shares in the last quarter. J.W. Cole Advisors Inc. acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $74,000. Finally, American Trust acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $414,000. 6.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Morgan Stanley raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Friday, July 15th. JPMorgan Chase & Co. raised Novo Nordisk A/S from a “neutral” rating to an “overweight” rating in a research report on Tuesday, June 7th. Guggenheim raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 31st. Exane BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a 750.00 target price for the company in a research report on Monday, June 27th. Finally, UBS Group cut Novo Nordisk A/S from a “neutral” rating to a “sell” rating in a research report on Tuesday, June 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $682.43.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $99.46 on Wednesday. The business’s fifty day moving average price is $108.23 and its two-hundred day moving average price is $109.44. The stock has a market cap of $225.07 billion, a PE ratio of 29.69, a price-to-earnings-growth ratio of 1.81 and a beta of 0.47. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.74 and a current ratio of 0.94. Novo Nordisk A/S has a one year low of $91.51 and a one year high of $122.16.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th were issued a dividend of $0.5836 per share. This represents a yield of 1.1%. The ex-dividend date of this dividend was Friday, August 12th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.18%.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Read More

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOGet Rating).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.